Research & Development News Channel

Cleveland Clinic study suggests steroid nasal sprays may help improve outcomes in severe COVID-19 disease

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 25% lower risk of hospitalization, ICU admission and mortality. The study was published in Journal of Allergy and Clinical Immunology: In Practice.

Discovery of mechanics of drug targets for COVID-19

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases such as cancer, rheumatoid arthritis, and even COVID-19. The findings published in Molecular Cell uncover the inner workings of cell receptors that are involved in cancer progression and inflammatory diseases.

Therapy using dual immune system cells effectively controls neuroblastoma

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue, report researchers from the UNC Lineberger Comprehensive Cancer Center and the UNC School of Medicine.

COVID-19 nasal vaccine candidate effective at preventing disease transmission

Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in developing intramuscular vaccines against SARS-CoV- 2, such as the readily available Pfizer, Moderna and Johnson & Johnson vaccines, nothing yet - like a nasal vaccine - has been approved to provide mucosal immunity in the nose, the first barrier against the virus before it travels down to the lungs.

How a plant virus could protect and save your lungs from metastatic cancer

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at bay from the lungs. The treatment not only slowed tumor growth in the lungs of mice with either metastatic breast cancer or melanoma, it also prevented or drastically minimized the spread of these cancers to the lungs of healthy mice that were challenged with the disease.

Scientific evidence to date on COVID-19 vaccine efficacy does not support boosters for general population

An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the general population are not appropriate at this stage in the pandemic.

The review, published in The Lancet, summarises the currently available evidence from randomised controlled trials and observational studies published in peer-reviewed journals and pre-print servers.

NIH scientists build a cellular blueprint of multiple sclerosis lesions

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms of the disease. Using brain tissue from humans, researchers at the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS) built a detailed cellular map of chronic MS lesions, identifying genes that play a critical role in lesion repair and revealing potential new therapeutic targets for progressive MS.

Research & Development News

Cleveland Clinic study suggests steroid nasal sprays may help improve outcomes in severe COVID-19 disease

Discovery of mechanics of drug targets for COVID-19

Therapy using dual immune system cells effectively controls neuroblastoma

COVID-19 nasal vaccine candidate effective at preventing disease transmission

How a plant virus could protect and save your lungs from metastatic cancer

Scientific evidence to date on COVID-19 vaccine efficacy does not support boosters for general population

NIH scientists build a cellular blueprint of multiple sclerosis lesions

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs